Ocugen, Inc.
Ocugen, Inc. (OCGN) appointed Jolanda Crombach as General Manager of its new European affiliate in Amsterdam to support its three Phase 3 gene therapy programs, aligning with its late-stage ophthalmology pipeline and anticipated EU submissions.
Ocugen, Inc. (OCGN) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On October 5, 2026, Ocugen, Inc. (the “Company”) reconvened its Special Meeting of Stockholders (the “Special Meeting”) virtually, which had been adjourned on September 21, 2026 solely with respect to the proposal to
The Third Circuit overturned a 30-year-old rule allowing companies to dismiss securities fraud lawsuits if stock prices recovered. The decision, involving Ocugen, Inc., means investors can now pursue claims even if stock prices rebound. Ocugen admitted to misstating financials, causing a temporary 10.38% stock drop. The case will return to district court for further review.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning OCGN (Ocugen, Inc.). Coverage has skewed bearish: 0 bullish, 1 neutral, and 2 bearish.
Recent OCGN coverage spans regulation, corporate actions and financial news.
In the last 30 days, OCGN insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($589K). The most active reporter was Musunuri Shankar, Chief Executive Officer, with 2 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The hire signals Ocugen's push into the European market for its Phase 3 gene‑therapy programs.
The vote could dilute existing shareholders if approved, creating downward pressure on the stock.
The legal reversal may increase litigation risk and pressure Ocugen's share price.
The approval opens a pathway for early patient access and may boost investor sentiment ahead of Phase 3 data.
The Bahamas approval expands access outside the U.S. and may boost investor sentiment.
AlphAI scores every news story that mentions OCGN with an AI model for sentiment and relevance, and aggregates insider trades from Ocugen, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Ocugen, Inc. (OCGN) appointed Jolanda Crombach as General Manager of its new European affiliate in Amsterdam to support its three Phase 3 gene therapy programs, aligning with its late-stage ophthalmology pipeline and anticipated EU submissions.
1 min readOcugen, Inc. (OCGN) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On October 5, 2026, Ocugen, Inc. (the “Company”) reconvened its Special Meeting of Stockholders (the “Special Meeting”) virtually, which had been adjourned on September 21, 2026 solely with respect to the proposal to
1 min readThe Third Circuit overturned a 30-year-old rule allowing companies to dismiss securities fraud lawsuits if stock prices recovered. The decision, involving Ocugen, Inc., means investors can now pursue claims even if stock prices rebound. Ocugen admitted to misstating financials, causing a temporary 10.38% stock drop. The case will return to district court for further review.
2 min readOcugen Inc. (OCGN) received provisional approval and priority designation from the Bahamas' LARTA Board for its gene therapy OCU400 to treat retinitis pigmentosa. The company plans to treat the first patient within 90 days of full approval and expects Phase 3 data in Q1 2027. OCU400 has received RMAT, Orphan Drug, and Orphan Medicinal Product designations from U.S. and EU regulators.
2 min readOcugen (OCGN) announced its gene therapy OCU400 received provisional approval in the Bahamas, aiming to treat the first retinitis pigmentosa patient within 90 days. Shares rose 3%. The company expects Phase 3 trial results in Q1 2027 and a U.S. BLA submission in Q2. Ocugen has other late-stage eye-disease programs and expects cash runway through 2028.
2 min readOcugen (OCGN) held a virtual meeting where 47.3% of shareholders approved adjourning to seek more votes on a 250M share increase. The meeting was rescheduled for October 5, 2026, with the July 27, 2026, record date intact. Shareholders can change their votes if desired.
1 min readOcugen, Inc. (OCGN) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On September 21, 2026, Ocugen, Inc. (the “Company”) held a Special Meeting of Stockholders (the “Special Meeting”) virtually, which was adjourned to October 5, 2026 solely with respect to the proposal to approve the a
1 min readMusunuri Shankar (Chief Executive Officer) sold 468,727 shares of Ocugen, Inc. (OCGN) at $1.12 ($0.52M total) on 2026-09-09 under a Rule 10b5-1 trading plan.
1 min readAnalysts maintained Buy ratings on Zymeworks (ZYME), Axsome Therapeutics (AXSM), and Ocugen (OCGN). ZYME's PT is $38 (Citi) and $40.20 (consensus). AXSM's PT is $256 (Wells Fargo) and $291 (consensus). OCGN's PT is $12 (Noble Financial) and $10.13 (consensus). All have Strong Buy consensus.
2 min readKowa Pharmaceuticals' NDA for K-911, an IOP-lowering eye drop, was accepted by the FDA, with a PDUFA target date of April 30, 2027. Ocugen dosed the first patient in a Phase 3 trial for OCU410, a gene therapy for dry AMD. Bausch + Lomb surveyed awareness of dry eye in menopause, finding low recognition. ASCRS announced events and policy statements. Research highlighted KLEx-CXL outcomes and enVista Aspire IOL performance.
2 min read
